Abstract 1251P
Background
Neutrality trial aims to analyze the prognostic role of blood biomarkes such as NLR (neutrophils to lymphocytes ratio), SII (Systemic Inflammatory Index-NLR x platelets), dNLR (neutrophil to leukocytes - neutrophil ratio) and LIPI (Lung Immune Prognostic Index) in stage III NSCLC patients (pts) treated with radiochemotherapy (RT-CHT) followed by Durvalumab (Cohort A), and in pts treated with RT-CHT alone (Cohort B).
Methods
NEUTRALITY is a retrospective multicentric observational study (ESR-19-20410). Blood count tests were recorded at the end of RT-CHT for Cohort B and during Durvalumab course for Cohort A. Different cut-offs of NLR, dNLR and SII were considered, based on the median values observed. Three LIPI index groups were analyzed: good (dNLR ≤ 3 and LDH ≤ UNL), intermediate (dNLR>; 3 or LDH ≥ UNL) and poor (dNLR>; 3 and LDH ≥ UNL). We performed a Cox-Regression analysis to correlate these biomarkers to overall survival (OS) and progression-free survival (PFS).
Results
Overall 190 pts (96 in Cohort A and 94 in Cohort B) were enrolled from 35 Italian Centers. Details of pts are shown in the table. For cohort A, we observed a significant correlation between baseline NLR, SII and dNLR with PFS: p 0.017, p 0.03 and p 0.018, respectively. LIPI was found to correlate with PFS too, with a better PFS in the good group, as expected (p 0.04). No correlation was found between these biomarkers and PFS and OS in Cohort B. Table: 1251P
Patients characteristics
| Cohort A patients (%) 96 | Cohort B patients (%) 94 | |
| Sex MF | 62 (64.5%)34 (35.5%) | 66 (70%)28 (30%) |
| Smoke YesNo | 85 (88%)9 (12%) | 85 (90%)9 (10%) |
| Age years MedianRange | 68 y44-83 | 66 y42-84 |
| Histology AdenocarcinomaSquamocellularOthers | 54 (56%)39 (41%)3 (3%) | 49 (52%)39 (41%)6 (7%) |
| PD-L1 expression 01-49≥ 50Not tested | 12 (12.5%)41 (43%)30 (31%)13 (13.5%) | 11 (12%)15 (16%)9 (10%)59 (62%) |
| Stage disease IIIAIIIBIIIC | 35 (36.5%)48 (50%)13 (13.5%) | 39 (41%)44 (47%)11 (12%) |
| ECOG PS 012 | 59 (61.5%)35 (37.5%)1 (1%) | 60 (64%)34 (36%)0 |
Conclusions
Our analysis suggests that blood inflammatory biomarkers can have a prognostic role for stage III NSCLC treated as per Pacific regimen. Further analysis are still ongoing to compare the two cohorts.
Clinical trial identification
ESR-19-20410.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1261P - Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutations
Presenter: Jie Wang
Session: Poster session 05
1262P - Combined molecular analysis of circulating tumour DNA and tumour tissue to identify osimertinib resistance
Presenter: Tijmen van der Wel
Session: Poster session 05
1263P - Biomarker analysis of plasma samples in YAMATO study: A randomized phase II trial comparing switching treatment of osimertinib following 8 months of afatinib (A) and osimertinib alone (B) in untreated advanced NSCLC patients with common EGFR mutation (TORG1939/WJOG12919L)
Presenter: Hiroshige Yoshioka
Session: Poster session 05
1264P - Real-world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Presenter: John Heymach
Session: Poster session 05
1265P - A promising MET-EGFR bispecific nanobody-drug conjugate therapy for multiple solid tumours
Presenter: xianghai Cai
Session: Poster session 05
1266P - Interim analysis from the multicenter ROSE study: Radiation during osimertinib treatment safety and efficacy cohort
Presenter: Amanda Tufman
Session: Poster session 05
1267P - Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: Primary analysis of Gio-Tag Japan, a multicenter prospective observational study
Presenter: Naoto Takase
Session: Poster session 05
1268P - Concordances assessment between MET-positive circulating tumour cells and disease progression in patients with EGFR mutated NSCLC
Presenter: Jieun Park
Session: Poster session 05
1269P - Preventing infusion-related reactions with intravenous amivantamab: Updated results from SKIPPirr, a phase II study
Presenter: Luis Paz-Ares
Session: Poster session 05
1270P - Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A single-arm, phase II multi-center trial
Presenter: Sehhoon Park
Session: Poster session 05